Thank you for your request

Please enter your email address and select the presentations/posters you would like to receive.


We use the data you enter on this form only for the purpose of sending you the requested materials. We will not use your contact details to contact you for any other purposes unless you have elsewhere provided your explicit consent to such communication. By pressing the “Accept and Send” button, you confirm that you accept the terms and conditions for the handling of any personal data submitted, as outlined in our Privacy Policy.

Contact Details

Required field.

Congress Assets

  • Select All
  • AAN Presentation 2019: Update from SUNFISH part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)
  • AAN Presentation 2019: Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling strategy to support RG6042 dose selection in Huntington’s disease (HD)
  • AAN Presentation 2019: FIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916)
  • AAN Poster 2019: Preliminary reliability and validity of a novel digital biomarker smartphone application to assess cognitive and motor symptoms in Huntington’s disease (HD)
  • AAN Poster 2019 VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With ▼Ocrelizumab
  • AAN Presentation 2019: Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies
  • AAN Presentation 2019: Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses of ▼Ocrelizumab in Patients with Multiple Sclerosis
  • AAN Poster 2019: A Phase 1b/2 study of the anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy: A 72-week treatment update
  • AAN Poster 2019: Safety of ▼Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
  • AAN Poster 2019 FLOODLIGHT: Smartphone-Based Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures
  • AAN Presentation 2019: One-year interim analysis results of the Phase IIIb CHORDS study evaluating ▼ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments
  • AAN Poster 2019: Reduced Rate of Brain Atrophy in Patients with PPMS Receiving ▼Ocrelizumab Earlier and Continuously Versus Those Initiating ▼Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up Supplemental Material
  • AAN Poster 2019: Defining clinically meaningful change on the composite Unified Huntington’s Disease Rating Scale (cUHDRS)
  • AAN Poster 2019: ▼Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients With Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design
  • AAN Poster 2019: Evaluation of Shorter Infusion Times With ▼Ocrelizumab in Patients With Multiple Sclerosis
  • AAN Poster 2019: Safety of ▼Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis Supplemental Material
  • AAN Presentation 2019: ▼Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study
  • AAN Poster 2019: Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of ▼Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis
  • AAN Poster 2019: ▼Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients With Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design Supplemental Material
  • AAN Poster 2019: Reduced Rate of Brain Atrophy in Patients with PPMS Receiving ▼Ocrelizumab Earlier and Continuously Versus Those Initiating ▼Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up
  • AAN Poster 2019 FLOODLIGHT: Smartphone-Based Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures Supplemental Material
  • AAN Presentation 2019: FIREFISH Part 1: 1-year results on motor function in infants with Type 1 SMA
  • AAN Poster 2019: Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of ▼Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis

Required field.

Required field.